

Anxiolytics

Point-of-Sale (POS) edits are safety limitations that are automatically verified through computer programming at the time that a prescription claim is submitted at the pharmacy. These edits can be applied to *any* medication, whether or not it is listed in the Preferred Drug List / Non-Preferred Drug List (PDL/NPDL). The first section of this document is organized to follow the order of the therapeutic classes in the PDL/NPDL and explains the POS edits for those medications.

POS Abbreviations

AL – Age Limit	DD – Drug-Drug Interaction	MD – Maximum Dose Limit	TD - Therapeutic Duplication
BH – Behavioral Health Clinical Authorization for Children Younger than 7 Years of Age	DS – Maximum Days’ Supply Allowed	PR – Enrollment in a Physician-Supervised Program Required	UN – Drug Use Not Warranted
BY – Diagnosis Codes Bypass Some Requirements	DT – Duration of Therapy Limit	PU – Prior Use of Other Medication is Required	X – Prescriber Must Have ‘X’ DEA Number
CL – Additional Clinical Information is Required	DX – Diagnosis Code Requirement	QL – Quantity Limit	YQ – Yearly Quantity Limit
CU – Concurrent Use with Other Medication is Restricted	ER – Early Refill	RX – Specific Prescription Requirement	

Pharmacy Prior Authorization Phone Numbers for MCOs and FFS

Aetna Better Health of Louisiana **1-855-242-0802**

AmeriHealth Caritas Louisiana **1-800-684-5502**

Fee-for-Service (FFS) Louisiana Legacy Medicaid **1-866-730-4357**

Healthy Blue **1-844-521-6942**

Louisiana Healthcare Connections **1-888-929-3790**

UnitedHealthcare **1-800-310-6826**

Anxiolytics

POS Edits		
AL – Alprazolam XR, alprazolam ODT, and lorazepam ER (Loreev XR™) are limited to use in recipients who are at least 18 years of age.		
BH – Additional behavioral-health related clinical information (trial of behavioral therapy, etc.) is required for all agents, EXCEPT meprobamate, when requested for recipients who are younger than 7 years of age.		
BY – Bypass diagnosis codes can be found at THIS LINK . <ul style="list-style-type: none"> - Pharmacy claims for selected anxiolytics, when submitted with a seizure-related diagnosis code will bypass the behavioral-health clinical authorization requirement, the restriction on concurrent use with opioids, and quantity limits. - Pharmacy claims submitted with a diagnosis code for cancer or palliative end-of-life care will bypass the restriction on concurrent use of benzodiazepines with opioids. 		
CU Benzodiazepines are monitored at POS for concurrent use with opioids and buprenorphine-containing products Concurrent pharmacy claims for benzodiazepines and buprenorphine will deny. Incoming benzodiazepine pharmacy claims will deny when the recipient has an active prescription (a prescription in which the days' supply has not expired) for a buprenorphine-containing product for the use of used to treat opioid dependence. Incoming benzodiazepine pharmacy claims will deny when the recipient has an active prescription (a prescription in which the days' supply has not expired) for an opioid <u>analgesic (see BY for additional information)</u> .		
DX – Pharmacy claims for alprazolam ER and alprazolam ODT require an appropriate diagnosis code found at THIS LINK .		
PU – The pharmacy POS system will verify the following for pharmacy claims for lorazepam ER (Loreev XR™) – claim in the previous 30-day period for EITHER a quantity of 90 lorazepam IR tablets OR any quantity of lorazepam ER (Loreev XR™).		
QL – Selected agents have quantity limits as listed in the chart to the right.	Quantity Limits	
	Generic (Brand Example)	Quantity Limit
	Alprazolam (Xanax®)	90 units in 30 days
	Alprazolam ER (Xanax XR®)	30 units in 30 days
	Chlordiazepoxide (Librium®)	90 units in 30 days
	Clonazepam (Klonopin®)	90 units in 30 days
	Clorazepate (Tranxene T-Tab®)	90 units in 30 days
	Diazepam (Valium®)	90 units in 30 days
	Lorazepam (Ativan®)	90 units in 30 days
	Lorazepam (Ativan®) Injectable	No Quantity Limit Applicable
	Lorazepam ER (Loreev XR™)	90 units in 30 days
	Oxazepam	90 units in 30 days

Anxiolytics

POS Edits

TD – These agents are monitored at the pharmacy POS for duplication of therapy with each other, with oxybate (Xyrem®), and with oxybate salts (Xywav™).

Revision / Date	Implementation Date
Created POS Document	February 2020
Modified to apply new age requirement for behavioral health clinical authorization / September 2020	January 2021
Added Loreev XR™ to age, previous use, and quantity limit sections, formatting changes / November 2021	April 2022
<u>Modified wording for concurrent use with buprenorphine-containing products / February 2022</u>	<u>July 2022</u>